Connect to other sites within the UBM Medica Network
PARP* Inhibitors in BRCA-Associated Cancers
None; investigational agents olaparib (AZD2281) and BSI-201 are in phase I and II clinical trials; other PARP inhibitors under investigation include AGO 14699 (Pfizer), ABT-888 (Enzo), and MK4827 (Merck).
Coping With ‘Chemobrain’
Cognitive impairment, including memory loss, inability to concentrate, and difficulty multitasking, has become a widely recognized possible late effect of chemotherapy and cancer treatment.
Helping Patients to Cope With CIPN
Owing to the success of today’s cancer treatments, many cancer survivors are now living through and beyond the cancer experience.
Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most challenging and complex complications of cancer chemotherapy.
Health Literacy: Strategies for Avoiding Communication Breakdown
At least half of all Americans are at risk for consequences resulting from low health literacy
Genetics and Genomics: A New Frontier in Oncology
Lea and Calzone have provided an outstanding overview of genetics and genomic research applicable to the subspecialty of oncology nursing.
Integrating Genetics and Genomics Into Oncology Nursing
Genetic and genomic research is creating new and more individualized approaches to better manage a person's disease or predisposition to disease, including cancer.
Genetics, Genomics, and Cancer: The Future Is Now
As a new decade unfolds, we are very fortunate to have an increasing number of new interventions available because of the recent tremendous advances in genetics and genomics.